Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), announced availability of two paper abstracts and two poster abstracts scheduled to be presented at the American Glaucoma Society (AGS) 26th Annual Meeting, taking place March 3-6, 2016, in Fort Lauderdale, Florida.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) belongs to Healthcare sector. Its weekly performance is -7.71%. On last trading day company shares ended up at $15.08.
VeriSign, Inc. (NASDAQ:VRSN), announces that Verisign Director William L. Chenevich has informed the Company’s Board of Directors of his intention to retire from the Board at the end of his current term in May 2016. Mr. Chenevich has served as a director since Verisign’s founding in April 1995, and was Lead Independent Director from February 2009 to July 2015. Mr. Chenevich is a member of the Board’s Audit and Corporate Governance and Nominating Committees.
VeriSign, Inc. (NASDAQ:VRSN) shares advanced 1.26% in last trading session and ended the day at $88.64. VRSN Gross Margin is 81.80% and its return on assets is 14.80%. VeriSign, Inc. (NASDAQ:VRSN) quarterly performance is -2.49%.
On 29 February, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported Revenues totaled $7.8 million, including $3.9 million in net product sales of BELVIQ. Research and development expenses totaled $20.2 million. General and administrative expenses totaled $9.7 million.
On 03 March, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 0.65% and was closed at $1.56. ARNA EPS growth in last 5 year was 31.20%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is -17.89%.
Saga Communications (NYSE: SGA) declared a quarterly dividend of $0.25 per share, or $1 annualized. The dividend will be payable on April 15, 2016, to stockholders of record on March 28, 2016, with an ex-dividend date of March 23, 2016.
Saga Communications, Inc. (NYSEMKT:SGA) ended the last trading day at $39.92. Company weekly volatility is calculated as 4.40% and price to cash ratio as 12.27. Saga Communications, Inc. (NYSEMKT:SGA) showed a weekly performance of 2.62%.
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced that positive interim data from the Company’s phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease will be presented on March 3, 2016 at 3:15 PM PT at the Lysosomal Disease Network 12th Annual WORLDSymposium 2016 in San Diego, CA. PRX-102 is a recombinant plant cell expressed, Pegylated modified version of the human alpha-Galactosidase-A enzyme. A slide presentation featuring these data will be posted at the time of the presentation on the Company’s web site, under the Presentations tab.
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) shares advanced 5.83% in last trading session and ended the day at $0.89. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) quarterly performance is -16.13%.